Novo Nordisk Receives European Approval for Wegovy Pill as First Oral GLP-1 Therapy
The European Commission approved Novo Nordisk's once-daily oral weight loss drug, Wegovy (semaglutide 25 mg), marking the first approval of a GLP-1 receptor agonist in tablet form across EU member states. This decision expands Novo Nordisk’s obesity treatment franchise and follows prior approvals in several other countries.
Tickers: $NVO
Topics: drug approvals GLP-1 agonists healthcare obesity treatment